BioMarin Pharmaceutical

BMRN · Nasdaq · United States

Share price · BMRN

$61.43-5.56 (-8.30%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.1M (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BMRN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+5.0%

    Nothing announced by BMRN that day or the session before.

  2. 3 Nov 2026-3.1%
  3. 22 Oct 2026+2.6%
  4. 10 Aug 2026+7.9%
  5. 29 May 2026+8.6%
  6. 21 May 2026+7.8%

    Nothing announced by BMRN that day or the session before.

  7. 5 May 2026-4.0%
  8. 19 Dec 2025+17.7%

Share of unusual movement by asset

For each asset, the share of BMRN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Vosoritide (VOXZOGO)
events and moves
3shown from 8 days
Pegvaliase (PALYNZIQ)
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—5%
Other company news (earnings, financing, releases naming no asset)—38%
Sessions with no dated event—58%

Assets

(10 total)
10Total Assets
8Approved
0Phase 3 / Filed
2Phase 1–2 / Early
9Diseases
Quick filter:
Showing 10 of 10 assets
Target & Modality
Approved
Tripeptidyl peptidase 1 (TPP1) replacementProtein / enzyme therapeutic
Neuronal Ceroid Lipofuscinosis Type 2
Approved
N-acetylgalactosamine-6-sulfatase (GALNS) replacementProtein / enzyme therapeutic
Mucopolysaccharidosis Type IVA
Galsulfase(NAGLAZYME)
Approved
N-acetylgalactosamine 4-sulfatase (arylsulfatase B)Protein / enzyme therapeutic
Mucopolysaccharidosis Type VI
Laronidase(ALDURAZYME)
Approved
Alpha-L-iduronidase (IDUA)Protein / enzyme therapeutic
Mucopolysaccharidosis Type I
Migalastat(Galafold)
Approved
Alpha-galactosidase A (GLA / α-Gal A)Small molecule
Fabry Disease
Pegvaliase(PALYNZIQ)
Approved
Phenylalanine ammonia lyase (enzyme substitution)Protein / enzyme therapeutic
Phenylketonuria
Approved
Phenylalanine hydroxylase (PAH)Small molecule
Phenylketonuria
Vosoritide(VOXZOGO)
Approved
Natriuretic peptide receptor B (NPR-B)Peptide
AchondroplasiaHypochondroplasia
Phase 2/3
C-type natriuretic peptide (CNP) pathwayPeptide
Achondroplasia
Phase 1/2
DMD exon 51RNA / oligonucleotide
Duchenne Muscular Dystrophy

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Migalastat · GalafoldPhase 3Fabry Disease
Est. primary completion 2026-12-31 · NCT04020055 · CT.gov ↗
What to watch
2027 (4)
April 2027 (1)
Nivudirsen (BMN 351)Phase 1/2Duchenne Muscular Dystrophy
Est. primary completion 2027-04-14 · NCT06280209 · CT.gov ↗
What to watch
December 2027 (3)
Vosoritide · VOXZOGOPhase 2Achondroplasia
Est. primary completion 2027-12 · NCT02724228 · CT.gov ↗
What to watch
Vosoritide · VOXZOGOPhase 2Achondroplasia
Est. primary completion 2027-12 · NCT04554940 · CT.gov ↗
What to watch
Migalastat · GalafoldPhase 3Fabry Disease
Est. primary completion 2027-12 · NCT06904261 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Vosoritide · VOXZOGOPhase 2Hypochondroplasia
Est. primary completion 2028-06-30 · NCT07126262 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
BMN 333Phase 2/3Achondroplasia
Est. primary completion 2029-06 · NCT07441876 · CT.gov ↗
What to watch
2031 (2)
June 2031 (1)
Vosoritide · VOXZOGOPhase 3Achondroplasia
Est. primary completion 2031-06 · NCT03424018 · CT.gov ↗
What to watch
December 2031 (1)
Nivudirsen (BMN 351)Phase 2Duchenne Muscular Dystrophy (DMD)
Est. primary completion 2031-12 · NCT07573631 · CT.gov ↗
What to watch
2038 (1)
May 2038 (1)
Vosoritide · VOXZOGOPhase 2Achondroplasia
Est. primary completion 2038-05 · NCT03989947 · CT.gov ↗
What to watch
2044 (1)
October 2044 (1)
Vosoritide · VOXZOGOPhase 3Hypochondroplasia
Est. primary completion 2044-10 · NCT07073014 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

28 February 2027FDA action dateVosoritideVOXZOGO achondroplasia sNDA (long-term data) PDUFA target action date
US, FDA · BioMarin Pharmaceutical · Source ↗

Recent

9 September 2026Filing submittedVosoritideBioMarin announces it has submitted an sNDA to the FDA for VOXZOGO (vosoritide) in hypochondroplasia (announced 2026-09-09; submission date not disclosed)
US, FDA · BioMarin Pharmaceutical · Source ↗
June 2026ApprovalPegvaliaseEuropean Commission approves Palynziq for adolescents with PKU
EU, European Commission · Source ↗
20 May 2026Topline resultVosoritidePhase 3 CANOPY-HCH-3 (NCT06455059) of vosoritide in children with hypochondroplasia met its primary endpoint (annualized growth velocity at week 52)
BioMarin Pharmaceutical · Source ↗
18 May 2026Topline resultBMN 401 (INZ-701)BMN 401 Phase 3 ENERGY 3 met one of two co-primary endpoints
BioMarin Pharmaceutical · Source ↗
27 February 2026ApprovalPegvaliaseFDA approves PALYNZIQ for ages 12 and older
US, FDA · BioMarin Pharmaceutical · Source ↗
29 October 2025Filing acceptedPegvaliaseFDA accepts sBLA for priority review (adolescents)
US, FDA · BioMarin Pharmaceutical · Source ↗
2 April 2025Topline resultPegvaliasePEGASUS phase 3 topline
BioMarin Pharmaceutical · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.0B—$736M+ $0 short-term inv.$123M$188M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$990M$207M$874M+ $0 short-term inv.—$168M operating cash flowreport ↗
2026-Q1$766M$179M$3.1B+ $0 short-term inv.—$221M operating cash flowreport ↗
2025-Q3$776M$409M$1.3B+ $228M short-term inv.$31M$369M operating cash flowreport ↗
2025-Q2$825M$161M$1.2B+ $218M short-term inv.—$185M operating cash flowreport ↗
2025-Q1$745M$159M$1.0B+ $224M short-term inv.—$174M operating cash flowreport ↗
2024-Q3$746M$185M$675M+ $255M short-term inv.—$221M operating cash flowreport ↗
2024-Q2$712M$184M$972M+ $252M short-term inv.—$119M operating cash flowreport ↗
2024-Q1$649M$205M$747M+ $300M short-term inv.—$47M operating cash flowreport ↗
2023-Q3$581M$191M$785M+ $340M short-term inv.—$136M operating cash flowreport ↗
2023-Q2$595M$177M$694M+ $477M short-term inv.—$70M operating cash flowreport ↗
2023-Q1$596M$172M$580M+ $572M short-term inv.—-$74M operating cash flowreport ↗
2022-Q3$505M$158M$762M+ $512M short-term inv.$6.7M$158M operating cash flowreport ↗
2022-Q2$534M$158M$620M+ $490M short-term inv.—$56M operating cash flowreport ↗
2022-Q1$519M$161M$605M+ $451M short-term inv.—-$45M operating cash flowreport ↗
2021-Q3$409M$158M$617M+ $462M short-term inv.$36M$97M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.2B$922M$1.3B+ $249M short-term inv.—$828M operating cash flowreport ↗

For full-year 2025, BioMarin reported revenue of $3,221.25M, up 12.9% YoY, with R&D spend of $921.93M, up 23.4% YoY. The company recorded net income of $348.9M and held cash and equivalents of $1,311.68M at year-end.

BioMarin provided 2026 guidance for total revenues of $3,325M to $3,425M and Non-GAAP diluted EPS of $4.95 to $5.15, excluding any post-close contribution from its announced acquisition of Amicus Therapeutics, which is expected to close in Q2 2026. Key pipeline updates included positive Phase 1 PK data for BMN 333, a Phase 3 hypochondroplasia readout for VOXZOGO expected in 1H 2026, and a PDUFA date of February 28, 2026 for the PALYNZIQ adolescent label expansion. The company also decided to voluntarily withdraw ROCTAVIAN from the market after failing to identify a buyer.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$2.9B$747M$943M+ $195M short-term inv.—$573M operating cash flowreport ↗
2023-FY$2.4B$747M$755M+ $319M short-term inv.—$159M operating cash flowreport ↗
2022-FY$2.1B$650M$725M+ $567M short-term inv.—$176M operating cash flowreport ↗
2021-FY$1.8B$629M$587M+ $427M short-term inv.$16M$305M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 6 sales ($4.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18Friberg Gregory R · EVP, Chief R&D OfficerOpen-market sale5,147$58.81$303KForm 4
2026-09-30Friberg Gregory R · EVP, Chief R&D OfficerTax withholding4,086$60.00$245KForm 4
2026-09-10Plenge Robert M · directorAward / grant6,140——Form 4
2026-09-02Davis George Eric · EVP, Chief Legal OfficerOpen-market sale17,557$66.28$1.2MForm 4
2026-06-02ANDERSON ELIZABETH M · directorAward / grant7,490——Form 4
2026-06-02Bodem Barbara W. · directorAward / grant7,490——Form 4
2026-06-02CLARK IAN T · directorAward / grant7,490——Form 4
2026-06-02Dere Willard H · directorAward / grant7,490——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 550 reporting institutions held 183.6M shares ($10.1B, 94.8% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.19,818,301$1.1B
2Dodge & Cox14,561,759$822.6M
3PRIMECAP MANAGEMENT CO/CA/14,194,005$801.8M
4VANGUARD CAPITAL MANAGEMENT LLC8,643,164$488.3M
5VANGUARD PORTFOLIO MANAGEMENT LLC8,298,475$468.8M
6AQR CAPITAL MANAGEMENT LLC7,676,541$429.3M
7STATE STREET CORP7,295,079$412.1M
8VIKING GLOBAL INVESTORS LP7,062,077$398.9M
9CITADEL ADVISORS LLC4,512,634$254.9M
10GEODE CAPITAL MANAGEMENT, LLC3,819,441$215.8M
11DIMENSIONAL FUND ADVISORS LP3,802,930$214.8M
12Vestal Point Capital, LP3,575,000$202.0M
13FMR LLC3,567,031$201.5M
14Capital Research Global Investors3,491,386$197.2M
15MILLENNIUM MANAGEMENT LLC3,010,308$170.1M